Cargando…

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five partici...

Descripción completa

Detalles Bibliográficos
Autores principales: McConnachie, Alex, Walker, Andrew, Robertson, Michele, Marchbank, Laura, Peacock, Julie, Packard, Christopher J., Cobbe, Stuart M., Ford, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909301/
https://www.ncbi.nlm.nih.gov/pubmed/23839541
http://dx.doi.org/10.1093/eurheartj/eht232
_version_ 1782301824226689024
author McConnachie, Alex
Walker, Andrew
Robertson, Michele
Marchbank, Laura
Peacock, Julie
Packard, Christopher J.
Cobbe, Stuart M.
Ford, Ian
author_facet McConnachie, Alex
Walker, Andrew
Robertson, Michele
Marchbank, Laura
Peacock, Julie
Packard, Christopher J.
Cobbe, Stuart M.
Ford, Ian
author_sort McConnachie, Alex
collection PubMed
description AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five participants aged 45–54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. RESULTS: Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. CONCLUSION: Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.
format Online
Article
Text
id pubmed-3909301
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-39093012014-02-03 Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study McConnachie, Alex Walker, Andrew Robertson, Michele Marchbank, Laura Peacock, Julie Packard, Christopher J. Cobbe, Stuart M. Ford, Ian Eur Heart J Clinical Research AIMS: To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS: Six thousand five hundred and ninety-five participants aged 45–54 years were randomized to 5 years treatment with pravastatin (40 mg) or placebo. Linkage to routinely collected health records extended follow-up for secondary healthcare resource utilization to 15 years. The following new results are reported: cause-specific first and recurrent cardiovascular hospital admissions including myocardial infarction, heart failure, stroke, coronary revascularization and angiography; non-cardiovascular hospitalization; days in hospital; quality-adjusted life years (QALYs); costs of pravastatin treatment, treatment safety monitoring, and hospital admissions. RESULTS: Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period. Benefits per 1000 subjects, attributable to prevention of cardiovascular events, included 163 fewer admissions and a saving of 1836 days in hospital, with fewer admissions for myocardial infarction, stroke, heart failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk. CONCLUSION: Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective. Oxford University Press 2014-02-01 2013-07-09 /pmc/articles/PMC3909301/ /pubmed/23839541 http://dx.doi.org/10.1093/eurheartj/eht232 Text en © The Author 2013. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
McConnachie, Alex
Walker, Andrew
Robertson, Michele
Marchbank, Laura
Peacock, Julie
Packard, Christopher J.
Cobbe, Stuart M.
Ford, Ian
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title_full Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title_fullStr Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title_full_unstemmed Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title_short Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
title_sort long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909301/
https://www.ncbi.nlm.nih.gov/pubmed/23839541
http://dx.doi.org/10.1093/eurheartj/eht232
work_keys_str_mv AT mcconnachiealex longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT walkerandrew longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT robertsonmichele longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT marchbanklaura longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT peacockjulie longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT packardchristopherj longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT cobbestuartm longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy
AT fordian longtermimpactonhealthcareresourceutilizationofstatintreatmentanditscosteffectivenessintheprimarypreventionofcardiovasculardiseasearecordlinkagestudy